Cardiovascular toxicities from systemic breast cancer therapy

Shuang Guo, Serena Wong

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Cardiovascular toxicity is unfortunately a potential short- or long-term sequela of breast cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and newer targeted agents such as trastuzumab can cause varying degrees of cardiac dysfunction. Type I cardiac toxicity is dose-dependent and irreversible, whereas Type II is not dose-dependent and is generally reversible with cessation of the drug. In this review, we discuss what is currently known about the cardiovascular effects of systemic breast cancer treatments, with a focus on the putative mechanisms of toxicity, the role of biomarkers, and potential methods of preventing and minimizing cardiovascular complications.

Original languageEnglish (US)
Article number346
JournalFrontiers in Oncology
Volume4
Issue numberDEC
DOIs
StatePublished - 2014

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Anthracycline
  • Breast cancer
  • Cardiotoxicity
  • Chemotherapy
  • Heart failure
  • Trastuzumab

Fingerprint

Dive into the research topics of 'Cardiovascular toxicities from systemic breast cancer therapy'. Together they form a unique fingerprint.

Cite this